Amphastar Pharmaceuticals (NASDAQ:AMPH) Hits New 1-Year Low – Here’s Why

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) hit a new 52-week low on Monday . The stock traded as low as $24.94 and last traded at $25.06, with a volume of 47436 shares traded. The stock had previously closed at $26.61.

Analyst Upgrades and Downgrades

Separately, Piper Sandler dropped their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Friday, March 21st.

Amphastar Pharmaceuticals Trading Down 6.6 %

The business’s 50-day simple moving average is $30.24 and its two-hundred day simple moving average is $39.18. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $1.18 billion, a PE ratio of 8.36, a PEG ratio of 2.19 and a beta of 0.79.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at $2,681,377.02. The trade was a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 27.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $38,000. Voloridge Investment Management LLC increased its holdings in Amphastar Pharmaceuticals by 16.2% in the fourth quarter. Voloridge Investment Management LLC now owns 143,436 shares of the company’s stock valued at $5,326,000 after buying an additional 19,991 shares during the last quarter. Squarepoint Ops LLC raised its stake in Amphastar Pharmaceuticals by 208.0% during the fourth quarter. Squarepoint Ops LLC now owns 17,664 shares of the company’s stock valued at $656,000 after buying an additional 11,929 shares in the last quarter. Twinbeech Capital LP bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $1,738,000. Finally, Systematic Financial Management LP acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $9,147,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.